Literature DB >> 25634813

Quercetin encapsulation in modified silica nanoparticles: potential use against Cu(II)-induced oxidative stress in neurodegeneration.

Christiane M Nday1, Eleftherios Halevas2, Graham E Jackson3, Athanasios Salifoglou4.   

Abstract

Neurodegenerative diseases entail deeply complex processes, intimately associated with progressive brain damage reflecting cellular demise. Biochemical reactivity linked to such processes in Alzheimer's disease involves, among others, metal-induced oxidative stress contributing to neuronal cell death. Prominent among redox active metals inducing oxidative stress is Cu(II). Poised to develop molecular technology counteracting oxidative stress, efforts were launched to prepare bioactive hybrid nanoparticles, capable of working as host-carriers of potent antioxidants, such as the natural flavonoid quercetin. Employing synthetic protocols consistent with the assembly of silica nanoparticles, PEGylated and CTAB-modified materials were synthesized. Subsequent concentration-dependent loading of quercetin led to well-defined molecular carriers, the antioxidant efficiency of which was determined through drug release studies using UV-visible spectroscopy. The physicochemical characterization (elemental analysis, particle size, z-potential, FT-IR, thermogravimetric analysis, scanning electron microscopy) of the empty and loaded silica nanoparticles led to the formulation of optimized material linked to the delivery of the encapsulated antioxidant to primary rat hippocampal cultures under oxidative stress. Entrapment and drug release studies showed a) the competence of hybrid nanoparticles as far as the loading capacity in quercetin (concentration dependence), b) congruence with the physicochemical features determined, and c) the release profile of the nanoparticle load under oxidative stress in neuronal cultures. The bio-activity profile of quercetin nanoparticles in a neurodegenerative environment brought on by Cu(II) a) denotes the improved specificity of antioxidant reactivity counteracting oxidative stress, and b) sets the stage for the development of molecular protection and preventive medical nanotechnology of relevance to neurodegenerative Alzheimer's disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cu(II); Modified silica-nanoparticles; Neurodegeneration; Oxidative stress; Quercetin encapsulation

Mesh:

Substances:

Year:  2015        PMID: 25634813     DOI: 10.1016/j.jinorgbio.2015.01.001

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  8 in total

Review 1.  Nanotechnology to improve the Alzheimer's disease therapy with natural compounds.

Authors:  Maria João Ramalho; Stephanie Andrade; Joana Angélica Loureiro; Maria do Carmo Pereira
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

Review 2.  Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go.

Authors:  Pragya Prasanna; Arun Upadhyay
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-27

3.  Development and optimization of quercetin-loaded PLGA nanoparticles by experimental design.

Authors:  Lucia Ruxandra Tefas; Ioan Tomuţă; Marcela Achim; Laurian Vlase
Journal:  Clujul Med       Date:  2015-04-15

Review 4.  Flavonoids as Therapeutic Agents in Alzheimer's and Parkinson's Diseases: A Systematic Review of Preclinical Evidences.

Authors:  Roxana Braga de Andrade Teles; Tâmara Coimbra Diniz; Tiago Coimbra Costa Pinto; Raimundo Gonçalves de Oliveira Júnior; Mariana Gama E Silva; Érica Martins de Lavor; Antonio Wilton Cavalcante Fernandes; Ana Paula de Oliveira; Fernanda Pires Rodrigues de Almeida Ribeiro; Amanda Alves Marcelino da Silva; Taisy Cinthia Ferro Cavalcante; Lucindo José Quintans Júnior; Jackson Roberto Guedes da Silva Almeida
Journal:  Oxid Med Cell Longev       Date:  2018-05-10       Impact factor: 6.543

5.  Triple herbal extract DA-9805 exerts a neuroprotective effect via amelioration of mitochondrial damage in experimental models of Parkinson's disease.

Authors:  Jin Seok Jeong; Ying Piao; Sora Kang; Minuk Son; Young Cheol Kang; Xiao Fei Du; Jayoung Ryu; Young Woong Cho; Hai-Hua Jiang; Myung Sook Oh; Seon-Pyo Hong; Young J Oh; Youngmi Kim Pak
Journal:  Sci Rep       Date:  2018-10-29       Impact factor: 4.379

6.  Fabrication and evaluation of novel quercetin-conjugated Fe3O4-β-cyclodextrin nanoparticles for potential use in epilepsy disorder.

Authors:  Mona Hashemian; Maryam Ghasemi-Kasman; Shahram Ghasemi; Atefeh Akbari; Monire Moalem-Banhangi; Leila Zare; Seyed Raheleh Ahmadian
Journal:  Int J Nanomedicine       Date:  2019-08-13

Review 7.  Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.

Authors:  Tao Ming Sim; Dinesh Tarini; S Thameem Dheen; Boon Huat Bay; Dinesh Kumar Srinivasan
Journal:  Int J Mol Sci       Date:  2020-08-23       Impact factor: 5.923

8.  Ginsenoside F1 Protects the Brain against Amyloid Beta-Induced Toxicity by Regulating IDE and NEP.

Authors:  Yee-Jin Yun; Bong-Hwan Park; Jingang Hou; Jung-Pyo Oh; Jin-Hee Han; Sun-Chang Kim
Journal:  Life (Basel)       Date:  2022-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.